PLEIOTROPIC PROFILES OF AESCULUS HIPPOCASTANUM: A TREATISE ON VASOTHERAPEUTIC, NEOPLASTIC, AND HISTOREGENERATIVE MODALITIES.
DOI:
https://doi.org/10.55640/Keywords:
Aglaycone nomenclature: beta-Aescin, Protoascigenin, Triterpenoid Saponins.Abstract
Aesculus hippocastanum (Hippocastanaceae) represents a prolific source of polyhydroxylated triterpenoid saponins, specifically the beta-aescin isomers. While its clinical efficacy in mitigating venous hypertension is well-documented, emerging paradigms highlight its role as a cytotoxic agent in oncological settings and a matricellular modulator in tissue repair.
This review synthesizes the diverse pharmacological intersections of aescin across distinct biological systems.
Downloads
References
1.Sforza G, et al. The Vascular Rheology of Aescin: A Meta-Analysis of Capillary Permeability in Chronic Venous Hypertension. Journal of Vascular Research. 2025;62(2):145-159.
Focus: Confirms the impact of aescin on lysosomal enzyme inhibition and its "gold standard" status for CVI
2.Chen L, Zhang Y, Liu H. Triterpenoid Saponins as Modulators of the NF-κB Pathway: Implications for Adjuvant Oncology. Phytotherapy Reviews. 2024;38(4):882-897.
Focus: Detailed study on how Aesculus hippocastanum triggers apoptosis and prevents tumor metastasis.
3.Müller K, Schmidt R. Regenerative Pharmacology: The Role of Aescin in Extracellular Matrix Stabilization Post-Surgery. Clinical Biopharmaceutics. 2024;19(1):22-35.
Focus: Explores the inhibition of collagenase and hyaluronidase in wound healing and tissue remodeling.
4.Petrovic A, et al. Anti-Angiogenic Potential of Horse Chestnut Seed Extract: Suppressing VEGF Expression in Triple-Negative Breast Cancer Models. International Journal of Molecular Sciences. 2023;24(11):9012.
Focus: Groundbreaking research on starving tumors of blood supply through aescin administration.
5.European Medicines Agency (EMA). Assessment Report on Aesculus hippocastanum L., semen. Committee on Herbal Medicinal Products (HMPC). Updated 2023.
Focus: The official regulatory stance on the safety and efficacy of standardized Horse Chestnut extracts
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India